Abstract
ObjectivesThe goal of this study was to investigate the precise timeline of respiratory events occurring after the administration of two gadolinium-based contrast agents, gadoxetate disodium and gadoterate meglumine.Materials and methodsThis retrospective study examined 497 patients subject to hepatobiliary imaging using the GRASP MRI technique (TR/TE = 4/2 ms; ST = 2.5 mm; 384 × 384 mm). Imaging was performed after administration of gadoxetate (N = 338) and gadoterate (N = 159). All GRASP datasets were reconstructed using a temporal resolution of 1 s. Four regions-of-interest (ROIs) were placed in the liver dome, the right and left cardiac ventricle, and abdominal aorta detecting liver displacement and increasing vascular signal intensities over time. Changes in hepatic intensity reflected respiratory dynamics in temporal correlation to the vascular contrast bolus.ResultsIn total, 216 (67%) and 41 (28%) patients presented with transient respiratory motion after administration of gadoxetate and gadoterate, respectively. The mean duration from start to acme of the respiratory episode was similar (p = 0.4) between gadoxetate (6.0 s) and gadoterate (5.6 s). Its mean onset in reference to contrast arrival in the right ventricle differed significantly (p < 0.001) between gadoxetate (15.3s) and gadoterate (1.8 s), analogously to peak inspiration timepoint in reference to the aortic enhancement arrival (gadoxetate: 0.9s after, gadoterate: 11.2 s before aortic enhancement, p < 0.001).ConclusionsThe timepoint of occurrence of transient respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine differs significantly between both contrast agents while the duration of the event remains similar.Key Points• Transient respiratory anomalies following the administration of gadoterate meglumine occurred during a time period usually not acquired in MR imaging.• Transient respiratory anomalies following the administration of gadoxetate disodium occurred around the initiation of arterial phase imaging.• The estimated duration of respiratory events was similar between both contrast agents.
Highlights
It has been established that administration of gadoxetate disodium may lead to transient episodes of respiratoryEur Radiol inconsistencies, noticeable as breath-hold failures with subsequent tachypnea which possibly result in detrimental artifacts during arterial phase MR imaging [1, 2]
Golden-angle radial sparse parallel (GRASP) MRI, which is a relatively new MRI technique based on the compressed-sensing principle, has shown the ability to assess respiratory and hemodynamic metrics related to different gadolinium-based contrast agents, even during free-breathing image acquisition [13]
The final study population included for analyses comprised 257 patients of which 216 received gadoxetate disodium and 41 received gadoterate meglumine (Fig. 1)
Summary
Eur Radiol inconsistencies, noticeable as breath-hold failures with subsequent tachypnea which possibly result in detrimental artifacts during arterial phase MR imaging [1, 2] The incidence of this phenomenon associated with gadoxetate disodium administration has already been extensively assessed, in comparison with other gadolinium-based contrast agents [3,4,5,6,7,8,9,10]. Additional factors, such as a dose-dependency of the phenomenon’s occurrence, have been investigated [11, 12]. The pre-injection and contrast arrival phases, both of which are usually not included in clinical reconstructions, can be retrieved analogously
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
